A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
← catalyst calendarNCT06764771 · readout in 422 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
437estimated
Sites
8
Countries
Australia, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2027-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Malignant Tumors
Interventions
- Drug: BMS-986488
- Drug: Adagrasib — also filed as KRAZATI, BMS-986503, MRTX849
- Drug: Cetuximab — also filed as ERBITUX
- Drug: Nivolumab — also filed as OPDIVO, BMS-936558
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Adverse Events (AEs)
measured Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
Number of participants with Serious AEs (SAEs)
measured Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria
measured From first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)
Number of participants with AEs leading to discontinuation
measured Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)
Number of deaths
measured From time of informed consent up to 52 weeks after end of treatment visit
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed